查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1802954

全球肾上腺危机管理市场：预测至 2032 年－按治疗类型、给药途径、病患细分、分销管道、最终用户和地区进行分析

Adrenal Crisis Management Market Forecasts to 2032 - Global Analysis By Treatment Type, Route of Administration, Patient Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球肾上腺危像管理市场预计在 2025 年达到 26 亿美元，到 2032 年将达到 44 亿美元，预测期内的复合年增长率为 7.5%。

肾上腺危象的处理包括立即静脉或肌肉注射Hydrocortisone，随后用等渗盐水快速进行液体復苏。对于面临急性压力源（例如感染、创伤或手术）的肾上腺功能不全患者来说，这是一个至关重要的通讯协定。及时介入可预防休克、器官衰竭和死亡。持续使用Hydrocortisone并接受内分泌科医生的监测至关重要，直到临床完全康復。

根据美国卫生研究院 (NIH) 的数据，肾上腺危症）的盛行率约为每百万人 110-144 例。

自体免疫疾病盛行率不断上升

自体免疫疾病（例如爱迪生氏症、先天性肾上腺增生症增生和原发性肾上腺功能不全）的盛行率不断上升，大大推动了肾上腺危像管理市场的扩张。医疗专业人员诊断能力的提高和意识提升有助于早期发现。老年人口的成长，特别是那些容易罹患内分泌失调的老年人口，进一步刺激了市场需求。此外，慢性压力、环境毒素和饮食变化等生活方式因素与自体免疫疾病的盛行率上升有关。这种流行病学趋势需要强有力的治疗性介入和紧急管理通讯协定，这为专门从事肾上腺危象预防和治疗解决方案的製药公司和医疗设备製造商创造了巨大的市场机会。

医疗费用高昂

紧急Hydrocortisone注射、持续荷尔蒙补充疗法以及专业监测设备都需要大量的医疗费用。肾上腺功能不全的慢性性质使得患者需要终生治疗方法，从而对患者和医疗保健系统带来累积的成本压力。此外，某些治疗方法和诊断方法的保险覆盖范围有限，这加剧了经济挑战。新兴市场的经济负担尤其突出，这些市场的医疗基础设施和报销政策仍然不足，这可能会限制先进肾上腺危机管理解决方案的市场渗透率以及针对不同患者群体的采用。

用于患者监测和依从性的数位健康解决方案

具有皮质醇监测功能的可穿戴设备可实现即时生理追踪，并促进主动危机预防。智慧型手机应用程式提供服药提醒、压力水平监测和紧急应变通讯协定，从而改善患者预后。远端医疗平台将患者与内分泌科医生联繫起来，进行远距咨询和药物调整。此外，人工智慧演算法可以根据患者资料模式预测危机发作，从而实现预防性干预。新冠疫情加速了数位医疗的普及，为创新监测解决方案创造了良好的市场环境，这些解决方案可增强病患安全性，同时降低医疗成本和住院率。

新产品和套件的报销障碍

监管机构要求在核准报销之前，提供大量临床证据来证明成本效益和安全性。保险公司通常优先考虑成熟的治疗方法而非创新治疗方法，这限制了先进治疗方法的可近性。漫长的报销核准时间会延迟产品的商业化和打入市场策略。此外，不同地区和医疗体系的报销政策差异也使全球市场渗透变得复杂。这些挑战，特别影响急救注射器和新型诊断试剂套件，可能会阻碍创新技术的采用，并限制患者获得尖端肾上腺危像管理技术的机会，儘管这些技术可能具有潜在的临床益处。

COVID-19的影响：

COVID-19疫情对肾上腺危机管理市场造成了重大衝击，导致医疗服务中断、常规监测预约延误。肾上腺功能不全患者更容易受到感染疾病，需要加强预防措施并制定压力类固醇给药方案。此外，供应链中断影响了药物可得性，尤其是Hydrocortisone可的松製剂。随着医疗服务提供者寻求替代性咨询方法，远端医疗的采用激增，数位健康解决方案的整合也加速发展。此外，疫情凸显了紧急准备的重要性，推动了对用于危机管理的家用监测设备和自我管理套件的需求。

预测期内，糖皮质激素治疗领域预计将成为最大的市场

糖皮质激素治疗领域预计将在预测期内占据最大的市场占有率，这得益于其作为肾上腺功能不全和危象预防的主要治疗手段的根本性作用。Hydrocortisone仍然是荷尔蒙补充疗法的黄金标准，其有效性和安全性已得到大量临床证据的支持。此外，该领域提供多种剂型，包括口服片剂、注射液和紧急自动注射器，以满足不同患者的需求。成熟的治疗方案和医生对糖皮质激素给药的熟悉程度，有助于其维持市场领先地位。

预计小儿科在预测期内的复合年增长率最高

由于儿童先天性肾上腺疾病的认知度和诊断率不断提高，预计小儿科领域将在预测期内达到最高成长率。先天性肾上腺增生症和原发性肾上腺功能不全等早发性疾病需要根据儿童生理状况量身定制的专门治疗方法。此外，改进的新生儿筛检计画实现了早期发现，从而增加了对适合其年龄的治疗方案和监测设备的需求。儿科内分泌科医生和基层医疗医生对肾上腺危症识别意识的不断提高也使儿科领域受益。此外，家长对儿科肾上腺综合护理的认识和支持不断提高，也进一步推动了该领域的扩张。

比最大的地区

在预测期内，北美预计将占据最大的市场占有率，这得益于其先进的医疗基础设施、全面的保险覆盖以及强大的药物研发能力。该地区成熟的内分泌治疗中心和专业的肾上腺功能不全诊所为患者照护。此外，强大的法律规范确保了产品品质和安全，同时也促进了创新技术的采用。高昂的医疗支出和病患意识层级支持着先进的治疗方案和复杂的监测技术。政府推动的罕见疾病研究措施以及患者权益组织的发展也促进了市场的持续成长。

复合年增长率最高的地区：

预计亚太地区将在预测期内见证最高的复合年增长率，这得益于医疗基础设施的扩大、诊断能力的提高以及医疗专业人员疾病意识的不断增强。日益增长的经济繁荣推动了医疗支出的增加，使人们能够获得先进的治疗方法。此外，政府促进医疗服务和保险覆盖的措施也在推动市场渗透。该地区患者人数众多，内分泌疾病的流行病学监测也得到改善。内分泌学和急诊医学的医生培训计画的增加正在提高危机意识和管理能力。数位医疗技术的采用和远端医疗的整合进一步推动了亚太地区多元化医疗体系市场快速扩张。

给药途径

  • 静脉注射
  • 肌肉注射（IM）
  • 口服
  • 皮下给药

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

5. 全球肾上腺危机管理市场（依治疗类型）

  • 糖皮质激素治疗
    • Hydrocortisone（静脉注射/肌肉注射）
    • 地塞米松
    • 其他糖皮质激素
  • 盐皮质激素疗法（ludrocortisone）
  • 体液/电解质补充疗法
  • 辅助性治疗

6. 全球肾上腺危机管理市场（依给药途径）

  • 静脉注射（IV）
  • 肌肉注射（IM）
  • 口服
  • 皮下

7. 全球肾上腺危机管理市场（依患者细分）

  • 成人
  • 孩子们
  • 老年人
  • 新生

8. 全球肾上腺危机管理市场（依通路）

  • 医院药房
  • 零售药局
  • 网路药局
  • 专业药品经销商

9. 全球肾上腺危机管理市场（依最终用户）

  • 医院
  • 紧急护理中心
  • 专科诊所
  • 居家医疗
  • 门诊手术中心
  • 其他最终用户

10. 全球肾上腺危机管理市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Eton Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Antares Pharma
  • Sandoz International GmbH
  • Halozyme Therapeutics
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Mylan NV
  • Ferring Pharmaceuticals
  • Hikma Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Sanofi SA
  • Bayer AG
  • AstraZeneca plc
  • Amneal Pharmaceuticals
  • Endo International plc
Product Code: SMRC30480

According to Stratistics MRC, the Global Adrenal Crisis Management Market is accounted for $2.6 billion in 2025 and is expected to reach $4.4 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Adrenal crisis management involves the immediate administration of intravenous or intramuscular hydrocortisone, followed by rapid fluid resuscitation using isotonic saline. It is a critical protocol for patients with adrenal insufficiency facing acute stressors such as infection, trauma, or surgery. Timely intervention prevents shock, organ failure, and death. Continued hydrocortisone dosing and endocrinologist oversight are essential until full clinical recovery is achieved.

According to the National Institutes of Health (NIH), adrenal insufficiency, the primary risk factor for adrenal crisis, has a prevalence of approximately 110-144 cases per million population.

Market Dynamics:

Driver:

Rising prevalence of autoimmune disorders

The escalating incidence of autoimmune conditions such as Addison's disease, congenital adrenal hyperplasia, and primary adrenal insufficiency significantly drives the adrenal crisis management market expansion. Improved diagnostic capabilities and enhanced awareness among healthcare professionals contribute to earlier detection rates. The growing geriatric population, particularly susceptible to endocrine disorders, further amplifies market demand. Moreover, lifestyle factors, including chronic stress, environmental toxins, and dietary changes, have been linked to increased autoimmune disorder prevalence. This epidemiological trend necessitates robust therapeutic interventions and emergency management protocols, thereby creating substantial market opportunities for pharmaceutical companies and medical device manufacturers specializing in adrenal crisis prevention and treatment solutions.

Restraint:

High cost of treatment

Emergency hydrocortisone injections, continuous hormone replacement therapy, and specialized monitoring equipment require considerable healthcare expenditure. The chronic nature of adrenal insufficiency demands lifelong treatment regimens, creating cumulative cost pressures for patients and healthcare systems. Moreover, limited insurance coverage for certain therapeutic options and diagnostic procedures exacerbates affordability challenges. The economic strain is particularly pronounced in developing regions where healthcare infrastructure and reimbursement policies remain inadequate, potentially limiting market penetration and adoption of advanced adrenal crisis management solutions across diverse patient populations.

Opportunity:

Digital health solutions for patient monitoring and adherence

Wearable devices equipped with cortisol monitoring capabilities enable real-time physiological tracking, facilitating proactive crisis prevention. Smartphone applications provide medication reminders, stress level monitoring, and emergency response protocols, improving patient outcomes. Telemedicine platforms connect patients with endocrinologists for remote consultations and dosage adjustments. Moreover, artificial intelligence algorithms can predict crisis episodes based on patient data patterns, enabling preventive interventions. The COVID-19 pandemic has accelerated digital health adoption, creating favorable market conditions for innovative monitoring solutions that enhance patient safety while reducing healthcare costs and hospital readmissions.

Threat:

Reimbursement hurdles for newer products and kits

Regulatory agencies require extensive clinical evidence demonstrating cost-effectiveness and safety profiles before approving coverage. Insurance providers often prioritize established treatments over innovative solutions, limiting access to advanced therapeutic options. The lengthy reimbursement approval timeline delays product commercialization and market entry strategies. Moreover, varying reimbursement policies across different regions and healthcare systems complicate global market penetration efforts. These challenges particularly affect emergency injection devices and novel diagnostic kits, potentially hindering innovation adoption and restricting patient access to cutting-edge adrenal crisis management technologies despite their clinical benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the adrenal crisis management market through disrupted healthcare services and delayed routine monitoring appointments. Patients with adrenal insufficiency faced increased infection vulnerability, necessitating enhanced precautionary measures and stress-dose steroid protocols. Additionally, supply chain disruptions affected medication availability, particularly hydrocortisone products. Telemedicine adoption surged as healthcare providers sought alternative consultation methods, accelerating digital health solution integration. Moreover, the pandemic highlighted the importance of emergency preparedness, driving demand for home-based monitoring devices and self-administration kits for crisis management.

The glucocorticoid therapy segment is expected to be the largest during the forecast period

The glucocorticoid therapy segment is expected to account for the largest market share during the forecast period due to its fundamental role as the primary treatment modality for adrenal insufficiency and crisis prevention. Hydrocortisone remains the gold standard for hormone replacement therapy, with extensive clinical evidence supporting its efficacy and safety profile. Additionally, the segment encompasses various formulations, including oral tablets, injectable solutions, and emergency auto-injectors, catering to diverse patient needs. The well-established treatment protocols and physician familiarity with glucocorticoid administration contribute to sustained market leadership.

The paediatrics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatrics segment is predicted to witness the highest growth rate due to increasing recognition and diagnosis of congenital adrenal disorders in children. Early-onset conditions such as congenital adrenal hyperplasia and primary adrenal insufficiency require specialized treatment approaches tailored to pediatric physiology. Additionally, improved neonatal screening programs enable earlier detection, driving demand for age-appropriate therapeutic formulations and monitoring devices. The segment benefits from enhanced awareness among pediatric endocrinologists and primary care physicians regarding adrenal crisis recognition. Moreover, growing parental awareness and advocacy for comprehensive pediatric adrenal care further accelerates segment expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share through advanced healthcare infrastructure, comprehensive insurance coverage, and robust pharmaceutical research capabilities. The region benefits from established endocrinology treatment centers and specialized adrenal insufficiency clinics providing expert patient care. Additionally, strong regulatory frameworks ensure product quality and safety while facilitating innovation adoption. High healthcare expenditure and patient awareness levels support premium treatment options and advanced monitoring technologies. Government initiatives promoting rare disease research and patient advocacy organizations contribute to sustained market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure, increasing diagnostic capabilities, and rising disease awareness among healthcare professionals. Growing economic prosperity enables enhanced healthcare spending and access to advanced therapeutic options. Additionally, government initiatives promoting healthcare accessibility and insurance coverage expansion facilitate market penetration. The region benefits from a large patient population and improving epidemiological surveillance systems for endocrine disorders. Rising physician training programs in endocrinology and emergency medicine enhance crisis recognition and management capabilities. The digital health technology adoption and telemedicine integration further support rapid market expansion across diverse Asia Pacific healthcare systems.

Key players in the market

Some of the key players in Adrenal Crisis Management Market include Eton Pharmaceuticals, Takeda, Pfizer, Antares Pharma, Sandoz, Halozyme, Novartis, Teva, GSK, AbbVie, Mylan, Ferring, Hikma, Sun Pharma, Cipla, Sanofi, Bayer, AstraZeneca, Amneal, and Endo International.

Key Developments:

In July 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe form and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

In January 2022, Antares Pharma, Inc. a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai(TM) novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.

In June 2021, Eton Pharmaceuticals, Inc the U.S. marketer of ALKINDI SPRINKLE(R), a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject's ZENEO(R) hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Treatment Types Covered:

  • Glucocorticoid Therapy
  • Mineralocorticoid Therapy (Fludrocortisone)
  • Fluid & Electrolyte Replacement Therapy
  • Adjunctive Therapies

Route of Administrations:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Oral
  • Subcutaneous

Patient Groups Covered:

  • Adults
  • Pediatrics
  • Geriatrics
  • Neonates

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Drug Distributors

End Users Covered:

  • Hospitals
  • Emergency Care Centers
  • Specialty Clinics
  • Home Care Settings
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Adrenal Crisis Management Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Glucocorticoid Therapy
    • 5.2.1 Hydrocortisone (IV/IM)
    • 5.2.2 Dexamethasone
    • 5.2.3 Other Glucocorticoids
  • 5.3 Mineralocorticoid Therapy (Fludrocortisone)
  • 5.4 Fluid & Electrolyte Replacement Therapy
  • 5.5 Adjunctive Therapies

6 Global Adrenal Crisis Management Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Intravenous (IV)
  • 6.3 Intramuscular (IM)
  • 6.4 Oral
  • 6.5 Subcutaneous

7 Global Adrenal Crisis Management Market, By Patient Group

  • 7.1 Introduction
  • 7.2 Adults
  • 7.3 Pediatrics
  • 7.4 Geriatrics
  • 7.5 Neonates

8 Global Adrenal Crisis Management Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Drug Distributors

9 Global Adrenal Crisis Management Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Emergency Care Centers
  • 9.4 Specialty Clinics
  • 9.5 Home Care Settings
  • 9.6 Ambulatory Surgical Centers
  • 9.7 Other End Users

10 Global Adrenal Crisis Management Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Eton Pharmaceuticals
  • 12.2 Takeda Pharmaceutical Company Limited
  • 12.3 Pfizer Inc.
  • 12.4 Antares Pharma
  • 12.5 Sandoz International GmbH
  • 12.6 Halozyme Therapeutics
  • 12.7 Novartis AG
  • 12.8 Teva Pharmaceutical Industries Ltd.
  • 12.9 GlaxoSmithKline plc
  • 12.10 AbbVie Inc.
  • 12.11 Mylan N.V.
  • 12.12 Ferring Pharmaceuticals
  • 12.13 Hikma Pharmaceuticals
  • 12.14 Sun Pharmaceutical Industries Ltd.
  • 12.15 Cipla Ltd.
  • 12.16 Sanofi S.A.
  • 12.17 Bayer AG
  • 12.18 AstraZeneca plc
  • 12.19 Amneal Pharmaceuticals
  • 12.20 Endo International plc

List of Tables

  • Table 1 Global Adrenal Crisis Management Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Adrenal Crisis Management Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Adrenal Crisis Management Market Outlook, By Glucocorticoid Therapy (2024-2032) ($MN)
  • Table 4 Global Adrenal Crisis Management Market Outlook, By Hydrocortisone (IV/IM) (2024-2032) ($MN)
  • Table 5 Global Adrenal Crisis Management Market Outlook, By Dexamethasone (2024-2032) ($MN)
  • Table 6 Global Adrenal Crisis Management Market Outlook, By Other Glucocorticoids (2024-2032) ($MN)
  • Table 7 Global Adrenal Crisis Management Market Outlook, By Mineralocorticoid Therapy (Fludrocortisone) (2024-2032) ($MN)
  • Table 8 Global Adrenal Crisis Management Market Outlook, By Fluid & Electrolyte Replacement Therapy (2024-2032) ($MN)
  • Table 9 Global Adrenal Crisis Management Market Outlook, By Adjunctive Therapies (2024-2032) ($MN)
  • Table 10 Global Adrenal Crisis Management Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 11 Global Adrenal Crisis Management Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
  • Table 12 Global Adrenal Crisis Management Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
  • Table 13 Global Adrenal Crisis Management Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Adrenal Crisis Management Market Outlook, By Subcutaneous (2024-2032) ($MN)
  • Table 15 Global Adrenal Crisis Management Market Outlook, By Patient Group (2024-2032) ($MN)
  • Table 16 Global Adrenal Crisis Management Market Outlook, By Adults (2024-2032) ($MN)
  • Table 17 Global Adrenal Crisis Management Market Outlook, By Pediatrics (2024-2032) ($MN)
  • Table 18 Global Adrenal Crisis Management Market Outlook, By Geriatrics (2024-2032) ($MN)
  • Table 19 Global Adrenal Crisis Management Market Outlook, By Neonates (2024-2032) ($MN)
  • Table 20 Global Adrenal Crisis Management Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 21 Global Adrenal Crisis Management Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 22 Global Adrenal Crisis Management Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 23 Global Adrenal Crisis Management Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 24 Global Adrenal Crisis Management Market Outlook, By Specialty Drug Distributors (2024-2032) ($MN)
  • Table 25 Global Adrenal Crisis Management Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Adrenal Crisis Management Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 27 Global Adrenal Crisis Management Market Outlook, By Emergency Care Centers (2024-2032) ($MN)
  • Table 28 Global Adrenal Crisis Management Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 29 Global Adrenal Crisis Management Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 30 Global Adrenal Crisis Management Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 31 Global Adrenal Crisis Management Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.